Minimal Residual Disease-Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Abstract

We present a case of a 2-year-old male admitted to University Hospital Brno in November 2020 with disseminated NPM1-ALK-positive, CD30+ ALCL. At presentation, the child had skin, bone marrow, and generalized lymph node involvement, with a WBC count of 47 x 109/L with more than 30% of ALCL blasts in peripheral blood.

Keywords

• Aminopyridines
• Humans
• Lactams
• Lactams, Macrocyclic
• Lymphoma, Large-Cell, Anaplastic/drug therapy
• Neoplasm, Residual
• Pyrazoles/therapeutic use